Efectividad de baricitinib y tofacitinib frente a bDMARDs en AR: resultados de un estudio de cohorte utilizando los datos del registro nacional sueco

Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keac068

Data from the Swedish Rheumatology Quality Register and Swedish Registries, show a higher treatment retention and overall equivalent or better treatment response on baricitinib, compared with bDMARDs or tofacitinib, but no statistically significant differences between tofacitinib and bDMARDs.In this largest population-based study to date, comparing RA patients initiating baricitinib, tofacitinib or bDMARDs, Barbulescu, et al. help to fill some of the current knowledge gaps surrounding the efficacy of JAKinibs compared to bDMARDs.

Keywords:


Publication thumbnail: Efectividad de baricitinib y tofacitinib frente a bDMARDs en AR: resultados de un estudio de cohorte utilizando los datos del registro nacional sueco
LinkedIn